These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11227392)

  • 1. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings.
    Kanavos P
    Pharmacoeconomics; 2000 Dec; 18(6):523-32. PubMed ID: 11227392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outstanding regulatory aspects in the European pharmaceutical market.
    Kanavos P; Mossialos E
    Pharmacoeconomics; 1999 Jun; 15(6):519-33. PubMed ID: 10538326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-border issues in the provision of health services: are we moving towards a European health care policy?
    Kanavos P; McKee M
    J Health Serv Res Policy; 2000 Oct; 5(4):231-6. PubMed ID: 11184960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is parallel trade in medicines compatible with the single European market?
    Senior I
    Pharmacoeconomics; 1992; 1(Suppl 1):70-6. PubMed ID: 10172047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-border health care in the European Union: recent legal implications of 'Decker and Kohll'.
    Hermans HE
    J Eval Clin Pract; 2000 Nov; 6(4):431-9. PubMed ID: 11133126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the pharmaceutical market in Poland after accession to the European Union.
    Willert PL
    Eur J Health Econ; 2007 Dec; 8(4):347-57. PubMed ID: 17186200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel imports of pharmaceuticals in the European Union.
    Darbà J; Rovira J
    Pharmacoeconomics; 1998; 14 Suppl 1():129-36. PubMed ID: 10186474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single European currency and Monetary Union. Macroeconomic implications for pharmaceutical spending.
    Kanavos P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):9-20. PubMed ID: 10175989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gray marketing of pharmaceuticals.
    Chaudhry PE; Walsh MG
    J Health Care Mark; 1995; 15(3):18-22. PubMed ID: 10172516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drugs in the European Union: the health-market complex].
    Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
    Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has the European union achieved a single pharmaceutical market?
    Timur A; Picone G; DeSimone J
    Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.